graft vs host disease

Summary

Summary: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.

Top Publications

  1. ncbi Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
    Katarina Le Blanc
    Haematology Centre and Centre of Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Lancet 371:1579-86. 2008
  2. ncbi National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
    Alexandra H Filipovich
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 11:945-56. 2005
  3. ncbi Hematopoietic stem-cell transplantation
    Edward A Copelan
    Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, USA
    N Engl J Med 354:1813-26. 2006
  4. pmc Graft-versus-host disease
    James L M Ferrara
    University of Michigan, Pediatrics and Internal Medicine, Blood and Marrow Transplantation Program, Ann Arbor, MI 48109 5942, USA
    Lancet 373:1550-61. 2009
  5. pmc Advances in graft-versus-host disease biology and therapy
    Bruce R Blazar
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Nat Rev Immunol 12:443-58. 2012
  6. ncbi Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
    Loredana Ruggeri
    Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy
    Science 295:2097-100. 2002
  7. pmc IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease
    David Polchert
    Department of Surgery, University of Illinois Chicago, Chicago, IL 60612, USA
    Eur J Immunol 38:1745-55. 2008
  8. ncbi Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:804-11. 2009
  9. ncbi Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006
  10. pmc Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Blood 117:1061-70. 2011

Detail Information

Publications288 found, 100 shown here

  1. ncbi Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
    Katarina Le Blanc
    Haematology Centre and Centre of Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Lancet 371:1579-86. 2008
    ..Mesenchymal stem cells modulate immune responses in vitro and in vivo. We aimed to assess whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-stem-cell transplantation...
  2. ncbi National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
    Alexandra H Filipovich
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 11:945-56. 2005
    ..It is currently recommended that systemic therapy be considered for patients who meet criteria for chronic GVHD of moderate to severe global severity...
  3. ncbi Hematopoietic stem-cell transplantation
    Edward A Copelan
    Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, USA
    N Engl J Med 354:1813-26. 2006
  4. pmc Graft-versus-host disease
    James L M Ferrara
    University of Michigan, Pediatrics and Internal Medicine, Blood and Marrow Transplantation Program, Ann Arbor, MI 48109 5942, USA
    Lancet 373:1550-61. 2009
    ..We also summarise supportive-care measures that are essential for management of this medically fragile population...
  5. pmc Advances in graft-versus-host disease biology and therapy
    Bruce R Blazar
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Nat Rev Immunol 12:443-58. 2012
    ..This Review highlights the recent advances in understanding the pathophysiology of GVHD and its treatment, with a focus on manipulations of the immune system that are amenable to clinical application...
  6. ncbi Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
    Loredana Ruggeri
    Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy
    Science 295:2097-100. 2002
    ..NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation...
  7. pmc IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease
    David Polchert
    Department of Surgery, University of Illinois Chicago, Chicago, IL 60612, USA
    Eur J Immunol 38:1745-55. 2008
    ..006). MSC activation was dependent on the magnitude of IFN-gamma exposure, with increased IFN-gamma exposure leading to increased MSC suppression of GVHD. Activated MSC present a new strategy for preventing GVHD using fewer MSC...
  8. ncbi Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:804-11. 2009
    ..There was no difference with respect to safety or efficacy between the low and high Prochymal dose. In conclusion, Prochymal can be infused safely into patients with aGVHD and induces response in a high proportion of GVHD patients...
  9. ncbi Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006
    ..Mesenchymal stem cells (MSC) have immunomodulatory effects. The aim was to study the effect of MSC infusion on graft-versus-host disease (GVHD)...
  10. pmc Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Blood 117:1061-70. 2011
    ..These results set the stage for a definitive study of UCB Treg to determine its potency in preventing allogeneic aGVHD. This study is registered at http://www.clinicaltrials.gov as NCT00602693...
  11. ncbi Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells
    Ho Jin Shin
    Division of Hematology Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea
    Blood 118:2342-50. 2011
    ..These studies indicate that the pharmacologic stimulation of T cells with IL-2 and the suppression of Tcon proliferation with RAPA result in a selective expansion of functional Tregs and suppression of acute GVHD...
  12. ncbi Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
    Mauro Di Ianni
    Hematology and Clinical Immunology Section, Department of Clinical and Experimental Medicine, University of Perugia, Italy
    Blood 117:3921-8. 2011
    ..This study provides evidence that Tregs are a conserved mechanism in humans...
  13. ncbi Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients
    Hillard M Lazarus
    Department of Medicine, The University Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA
    Biol Blood Marrow Transplant 11:389-98. 2005
    ..The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials...
  14. pmc Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease
    John M Magenau
    Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA
    Biol Blood Marrow Transplant 16:907-14. 2010
    ..03). Treg frequency may therefore have important prognostic value as a biomarker of aGVHD...
  15. ncbi New perspectives on the biology of acute GVHD
    S Paczesny
    Department of Pediatrics, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Bone Marrow Transplant 45:1-11. 2010
    ..Herein, we provide a novel perspective on the immunobiology of acute GVHD and briefly discuss some of the outstanding questions and limitations of the model systems...
  16. pmc In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations
    Michael J Carlson
    Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA
    Blood 113:1365-74. 2009
    ..Finally, we demonstrate differential roles for tumor necrosis factor-alpha (TNF-alpha) and IL-17A in the clinical manifestations of GVHD induced by TH17 cells. Our studies demonstrate that cells other than TH1/Tc1 can mediate acute GVHD...
  17. ncbi Immunomodulation by mesenchymal stem cells and clinical experience
    K Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Intern Med 262:509-25. 2007
    ..Possible clinical applications include therapy-resistant severe acute graft-versus-host disease, tissue repair, treatment of rejection of organ allografts and autoimmune disorders...
  18. pmc Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation
    Petra Hoffmann
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, CA 94305, USA
    J Exp Med 196:389-99. 2002
    ..Our results demonstrate that the balance of donor-type CD4(+)CD25(+) T(reg) and conventional CD4(+)CD25(-) T cells can determine the outcome of aGVHD...
  19. ncbi The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality
    Patricia A Taylor
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, Minneapolis 55455, USA
    Blood 99:3493-9. 2002
    ..CD4(+)CD25(+) cells warrant consideration as an exciting new modality of cellular therapy for the inhibition of undesirable autologous and allogeneic responses...
  20. ncbi Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome
    Neal Flomenberg
    Department of Medicine and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Blood 104:1923-30. 2004
    ..When clinical circumstances allow, high-resolution class I typing may help optimize donor selection and improve outcome...
  21. pmc In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
    Jaebok Choi
    Division of Oncology, Department of Medicine, Washington University, St Louis, MO 63110, USA
    Blood 116:129-39. 2010
    ....
  22. ncbi Graft-versus-host disease
    Warren D Shlomchik
    Yale University School of Medicine, sections of Medical Oncology and Immunobiology, PO Box 208032, New Haven, Connecticut 06520, USA
    Nat Rev Immunol 7:340-52. 2007
    ..This Review focuses on research in mouse models pursued to achieve this goal...
  23. pmc Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study
    John E Levine
    University of Michigan Blood and Marrow Transplant Program, Ann Arbor, USA
    Blood 119:3854-60. 2012
    ..The study was registered in clinicaltrials.gov as NCT00224874...
  24. ncbi Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors
    Olaf Penack
    Department of Hematology and Oncology, Charite, Campus Benjamin Franklin, Berlin, Germany
    Blood 115:1865-72. 2010
    ..This review covers current knowledge of the role of PAMPs and PRRs in the control of adaptive immune responses during inflammatory diseases, particularly GVHD...
  25. pmc IL-17 contributes to CD4-mediated graft-versus-host disease
    Lucy W Kappel
    Department of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 113:945-52. 2009
    ..We conclude that IL-17 is dispensable for GVHD and GVT activity by whole T cells, but contributes to the early development of CD4-mediated GVHD by promoting production of proinflammatory cytokines...
  26. ncbi Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors
    Kieren A Marr
    Fred Hutchinson Cancer Research Center Programs in Infectious Diseases and Long term Follow up, Seattle, WA 98109, USA
    Blood 100:4358-66. 2002
    ....
  27. ncbi Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R
    Konrad Wilhelm
    Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwigs University, Freiburg, Germany
    Nat Med 16:1434-8. 2010
    ..These data have major implications for transplantation medicine, as pharmacological interference with danger signals that act via P2X(7)R could lead to the development of tolerance without the need for intensive immunosuppression...
  28. pmc Acute graft-versus-host disease: from the bench to the bedside
    Gerard Socie
    Service d Hématologie Greffe, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, université Paris VII Denis Diderot, and Unité Inserm U728, Paris, France
    Blood 114:4327-36. 2009
    ..In this review, we summarize some of the major advances in GVHD pathophysiology, including the translation of these from the bench to the bedside, and discuss preclinical approaches that warrant further exploration in the clinic...
  29. ncbi Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium
    M von Bonin
    Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus, Dresden, Germany
    Bone Marrow Transplant 43:245-51. 2009
    ..In our patient cohort, response to MSC transfusion was lower than in the series reported earlier. However, our experience supports the potential efficacy of MSC in the treatment of steroid-refractory aGVHD...
  30. ncbi Chronic graft-versus-host disease
    Mitchell E Horwitz
    Division of Cellular Therapy, Duke University Medical Center, 2400 Pratt Street DUMC 3961, Durham, NC 27710, USA
    Blood Rev 20:15-27. 2006
    ..Topical therapy to affected areas is preferred for patients with mild disease. The 10-year survival of patients with mild chronic GVHD is approximately 80%, but is less than 5% for patients affected by severe chronic GVHD...
  31. pmc Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease
    Tangsheng Yi
    Graduate School of Biological Science, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA
    Blood 112:2101-10. 2008
    ....
  32. ncbi Host-reactive CD8+ memory stem cells in graft-versus-host disease
    Yi Zhang
    Department of Medicine, University of Pennsylvania School of Medicine, Room 510, Maloney, 3600 Spruce Street, Philadelphia, Pennsylvania 19104, USA
    Nat Med 11:1299-305. 2005
    ..Memory stem cells will be important targets for understanding and influencing diverse chronic immune reactions, including GVHD...
  33. ncbi First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells
    Piotr Trzonkowski
    Department of Clinical Immunology and Transplantology, Medical University of Gdansk, ul Debinki 1, 80 211 Gdansk, Poland
    Clin Immunol 133:22-6. 2009
    ....
  34. ncbi Immunobiology of allogeneic hematopoietic stem cell transplantation
    Lisbeth A Welniak
    Department of Microbiology and Immunology, University of Nevada, Reno, Nevada 89557, USA
    Annu Rev Immunol 25:139-70. 2007
    ..We also review new strategies to optimize the GVT and improve overall immune function while reducing GVHD and graft rejection...
  35. pmc Mesenchymal stem cell as salvage treatment for refractory chronic GVHD
    J Y Weng
    Department of Haematology, Guangdong General Hospital, Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, Guangdong, PR China
    Bone Marrow Transplant 45:1732-40. 2010
    ..In conclusion, transfusion of MSCs expanded in vitro, irrespective of the donor, might be a safe and effective salvage therapy for patients with steroid-resistant, cGVHD...
  36. pmc Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
    Francisco M Marty
    Division of Infectious Diseases, Boston, MA 02115, USA
    Blood 110:490-500. 2007
    ..66; P = .14 and P = .35, respectively). The protective effect of sirolimus-containing GVHD prophylaxis regimens on CMV reactivation should be confirmed in randomized trials...
  37. ncbi Haematopoietic cell transplantation as immunotherapy
    F R Appelbaum
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D5-310, PO Box 19024, Seattle, Washington 98109-1024, USA
    Nature 411:385-9. 2001
    ..Recent advances in our understanding of the immunobiology of stem-cell engraftment, tolerance and tumour eradication are allowing clinicians to better harness this powerful effect...
  38. pmc The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation
    Vu H Nguyen
    Department of Medicine, Stanford University, CA, USA
    Blood 111:945-53. 2008
    ..These findings provide new insights into the role of Tregs in affording protection to lymphoid stromal elements important for T-cell immunity...
  39. ncbi MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease
    Markus M Heimesaat
    Institut für Mikrobiologie und Hygiene, Charite Universitatsmedizin, Campus Benjamin Franklin, Berlin, Germany
    Gut 59:1079-87. 2010
    ..The bacterial microflora aggravates graft-versus-host-disease (GvHD) after allogeneic stem cell transplantation, but the underlying mechanisms of manifestations of intestinal GvHD (iGvHD) in the gut remain poorly understood...
  40. pmc Validation of measurement scales in ocular graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ophthalmology 119:487-93. 2012
    ..Candidate scales were recommended for use in clinical trials by the National Institutes of Health (NIH) Chronic GVHD Consensus Conference or have been previously validated in dry eye syndromes...
  41. ncbi Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease
    Nathan Cantoni
    Division of Hematology, University Hospital Basel, Petersgraben 4, Basel, Switzerland
    Biol Blood Marrow Transplant 16:1309-14. 2010
    ..65, P < .01). These data confirm that GVHD and its therapy can induce CMV replication. They further demonstrate the reciprocal novel finding that patients are at significantly increased risk of developing aGVHD during CMV replication...
  42. ncbi Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study
    Vinod K Prasad
    The Pediatric Blood and Marrow Transplant Program, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    Biol Blood Marrow Transplant 17:534-41. 2011
    ....
  43. ncbi The best endpoint for acute GVHD treatment trials
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 115:5412-7. 2010
    ..No other differences in response by donor source were observed. These data suggest that day 28 is the best early endpoint for acute GVHD therapeutic trials in predicting 2-year TRM...
  44. ncbi Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
    ..Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma...
  45. ncbi Target antigens determine graft-versus-host disease phenotype
    Daniel H Kaplan
    Departments of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Immunol 173:5467-75. 2004
    ..Thus, the selection of immunodominant Ags determines the target and character of GVHD, providing insight into the genetic basis for different forms of GVHD...
  46. pmc Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network prot
    Steven M Devine
    Medicine Department of Ohio State University, Columbus, Ohio, USA
    Biol Blood Marrow Transplant 17:1343-51. 2011
    ..HCT after myeloablative chemoradiotherapy can be performed in a multicenter setting using a uniform method of TCD, resulting in a low risk of extensive chronic GVHD and relapse for patients with AML in CR1...
  47. pmc Plasma biomarkers of lower gastrointestinal and liver acute GVHD
    Andrew C Harris
    Blood and Marrow Transplant Program, The University of Michigan, Ann Arbor, MI 48109 5942, USA
    Blood 119:2960-3. 2012
    ..02, respectively). Liver GVHD without GI involvement at GVHD onset and non-GVHD liver complications were uncommon; all 3 biomarkers were elevated in liver GVHD, but did not distinguish GVHD from other causes of hyperbilirubinemia...
  48. ncbi Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells
    Kang Hsi Wu
    School of Chinese Medicine, China Medical University, Taichung, Taiwan
    Transplantation 91:1412-6. 2011
    ..Bone marrow-derived mesenchymal stem cells (BMMSC) have been found to be immunosuppressive, and intravenous infusion of BMMSC is an effective therapy for steroid-resistant aGVHD. However, acquiring BMMSC requires an invasive procedure...
  49. ncbi Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
    Evelien Kneppers
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 118:2413-9. 2011
    ..This trial was registered at www.trialregister.nl as #NTR1645...
  50. pmc Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies
    Robert J Soiffer
    Dana Farber Cancer Institute, Boston, MA, USA
    Blood 117:6963-70. 2011
    ..001). Corresponding probabilities of overall survival were 50%, 38%, and 46% (P = .008). These data suggest adopting a cautious approach to routine use of in vivo T-cell depletion with RIC regimens...
  51. pmc Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease
    Ran Reshef
    Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    N Engl J Med 367:135-45. 2012
    ..The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans...
  52. pmc Graft versus host disease in the bone marrow, liver and thymus humanized mouse model
    Matthew B Greenblatt
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS ONE 7:e44664. 2012
    ..The presence of xenogenic GVHD in BLT mice both presents a major obstacle in the use of humanized mice and an opportunity to conduct preclinical studies on GVHD in a humanized model...
  53. pmc Discovery and validation of graft-versus-host disease biomarkers
    Sophie Paczesny
    Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI, USA
    Blood 121:585-94. 2013
    ..This review identifies biomarkers for detecting GVHD, summarizes current information on aGVHD biomarkers, proposes future prospects for the blinded evaluation of these biomarkers, and discusses the need for biomarkers of chronic GVHD...
  54. ncbi Administration of hydrogen-rich saline protects mice from lethal acute graft-versus-host disease (aGVHD)
    Liren Qian
    Department of Haematology, Naval General Hospital, Beijing, PR China
    Transplantation 95:658-62. 2013
    ..Therefore, we hypothesized that hydrogen may have therapeutic effects on aGVHD...
  55. pmc Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
    John E Levine
    Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA
    Blood 111:2470-5. 2008
    ..We conclude that etanercept plus steroids as initial therapy for acute GVHD results in a substantial majority of CRs. This trial was referenced at www.clinicaltrials.gov as NCT00141713...
  56. ncbi Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies
    Michael Boeckh
    University of Washington, Seattle, WA 81009, USA
    Biol Blood Marrow Transplant 9:543-58. 2003
    ....
  57. pmc Interferon regulatory factor 8 integrates T-cell receptor and cytokine-signaling pathways and drives effector differentiation of CD8 T cells
    Fumi Miyagawa
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 109:12123-8. 2012
    ....
  58. ncbi PI3Kγ controls leukocyte recruitment, tissue injury, and lethality in a model of graft-versus-host disease in mice
    Marina G M Castor
    Laboratorio de Imunofarmacologia, Departamento de Bioquimica e Imunologia, Universidade Federal de Minas Gerais, Av Antonio Carlos, 6627, Pampulha 31270 901, Belo Horizonte, MG, Brazil
    J Leukoc Biol 89:955-64. 2011
    ..In conclusion, PI(3)Kγ plays a critical role in GVHD by mediating leukocyte influx and activation in tissues. PI(3)Kγ inhibitors may be useful in the treatment of GVHD in patients undergoing BMT...
  59. ncbi Are we making progress in GVHD prophylaxis and treatment?
    Steven Z Pavletic
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Hematology Am Soc Hematol Educ Program 2012:251-64. 2012
    ....
  60. ncbi Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation
    Z McIver
    Experimental Hematology and Hematopoiesis Section, Cleveland, OH 44195, USA
    Br J Haematol 141:170-8. 2008
    ..All individuals who demonstrated more than 1% DN Tregs did not develop GvHD, providing evidence that DN Tregs participate in peripheral tolerance to prevent GvHD when expanded after allogeneic HSCT...
  61. ncbi Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD
    S Thiant
    Universite Lille Nord de France, Lille, France
    Bone Marrow Transplant 46:1374-81. 2011
    ..In multivariate analysis, IL-7 level measured on day +30 was the foremost predictive factor for grade 2-4 acute GVHD (P=0.002). Measurement of IL-7 level after RIC transplantation might help predict risk of subsequent acute GvHD...
  62. pmc Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance
    J Leventhal
    Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, Illinois, USA
    Clin Pharmacol Ther 93:36-45. 2013
    ..This review presents a historic perspective of the quest for tolerance in organ transplantation, highlighting current clinical approaches...
  63. ncbi Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
    Tomomi Toubai
    Blood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0942, USA
    Curr Stem Cell Res Ther 7:229-39. 2012
    ..In this review, we summarize the roles of individual cytokines in the pathophysiology of acute GVHD and discuss the possibility of cytokines as biomarkers of acute GVHD after allo-HCT...
  64. ncbi Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease
    Ulrich A Duffner
    Department of Internal Medicine, University of Michigan Cancer Center, Ann Arbor, MI 48109, USA
    J Immunol 172:7393-8. 2004
    ..These results demonstrate that host-derived DCs are critical in priming donor CD4(+) and CD8(+) T cells to cause GVHD, and selective targeting of host DCs may be a promising strategy to prevent GVHD...
  65. ncbi Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning
    Frederic Baron
    Department of Medicine, Division of Hematology, CHU of Liege, Liege, Belgium
    Biol Blood Marrow Transplant 16:838-47. 2010
    ..02), and 38% (P = .1), respectively, and a 1-year rate of death from GVHD or infection with GVHD of 31% (P = .04). In conclusion, our data suggest that HLA-mismatched NMA HCT with MSC coinfusion appeared to be safe...
  66. ncbi Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation
    Philipp Yorck Herzberg
    Department of Medical Psychology and Sociology, University of Leipzig, Leipzig, Germany
    Biol Blood Marrow Transplant 16:1707-17. 2010
    ....
  67. ncbi Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells
    Raewyn Broady
    Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Blood 116:5748-51. 2010
    ..These data support the long-standing paradigm that tissue localized interferon-γ-producing cells are the perpetrators of aGVHD...
  68. ncbi Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation
    M E Bernardo
    Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Bone Marrow Transplant 46:200-7. 2011
    ..Although these data do not support the use of MSCs in UCBT to support hematopoietic engraftment, they suggest that MSCs, possibly because of their immunosuppressive effect, may abrogate life-threatening acute GVHD and reduce early TRM...
  69. ncbi The impact of anti-HLA antibodies on unrelated cord blood transplantations
    Minoko Takanashi
    Japanese Red Cross Tokyo Blood Center, Tokyo, Japan
    Blood 116:2839-46. 2010
    ..23, 95% CI, 0.09-0.56, P = .001) and platelet recovery (RR = 0.31, 95% CI, 0.12-0.81, P = .017) than the ab-negative. Patients' pretransplantation anti-HLA antibodies should be tested and considered in the selection of cord blood...
  70. ncbi High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism
    Takakazu Kawase
    Division of Immunology, Aichi Cancer Center, Nagoya, Japan
    Blood 110:2235-41. 2007
    ..Furthermore, the identification of high-risk mismatch, that is, nonpermissive mismatch, would be beneficial for the selection of a suitable donor...
  71. ncbi Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD)
    Tinghua Cao
    THERAKOS Inc, Exton, PA 19341, USA
    Cell Immunol 258:65-71. 2009
    ..These results demonstrated that ex vivo expanded human Tregs retained their in vivo suppressive activity and prevented lethal xenogeneic GVHD, revealing the therapeutic potential of expanded human Tregs for GVHD...
  72. ncbi Immunomodulatory properties of mesenchymal stem cells: cytokines and factors
    Ehsan Soleymaninejadian
    Center for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, India
    Am J Reprod Immunol 67:1-8. 2012
    ....
  73. pmc Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease
    John Wilson
    Mater Medical Research Institute, South Brisbane, Queensland 4101, Australia
    J Exp Med 206:387-98. 2009
    ..Antibodies that target activated DC are a promising new therapeutic approach to the control of GVHD...
  74. pmc Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 26:4912-20. 2008
    ..Here, we have extended the follow-up to a median of 5 years and have included data on an additional 18 patients...
  75. pmc Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease
    Emmanuel Zorn
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:2903-11. 2005
    ..These findings support the development of new strategies to increase the number of Tregs following allogeneic hematopoietic stem cell transplantation to prevent or correct cGVHD...
  76. ncbi Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation
    Emmanuel Clave
    Assistance Publique Hopitaux de Paris, Inserm Unite Mixte de Recherche, Institut Universitaire d Hematologie, Universite Paris, Diderot, France
    Blood 113:6477-84. 2009
    ..These data show that aGVHD or its treatment has a transient impact on thymic function in younger patients in the first months after HSCT...
  77. ncbi New approaches for improving engraftment after cord blood transplantation
    Vanderson Rocha
    Universite de Paris 7, Hospital Saint Louis, Paris, France
    Biol Blood Marrow Transplant 16:S126-32. 2010
    ..Those approaches may greatly increase the quality and availability of CB for transplantation...
  78. pmc The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations
    Hongbo Wang
    Department of Pediatrics, Cancer Center, University of Minnesota, Minneapolis, USA
    Blood 110:1530-9. 2007
    ..Collectively, these studies show that CSA influences NK-cell function and phenotype, which may have important implications for graft-versus-leukemia effects...
  79. ncbi Human regulatory T cells in allogeneic stem cell transplantation
    Sya N Ukena
    Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    Blood 118:e82-92. 2011
    ..These results point to a reduced suppressive function of Tregs from GVHD patients with diminished migration capacity to the target organs...
  80. pmc Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease
    Hiroki Tsukamoto
    Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Blood 119:4554-64. 2012
    ....
  81. ncbi Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia
    Mary J Laughlin
    Case Comprehensive Cancer Center and University Hospitals of Cleveland Ireland Cancer Center, Cleveland, USA
    N Engl J Med 351:2265-75. 2004
    ..Data regarding the outcome of cord-blood transplantation in adults are scant, despite the fact that these grafts are increasingly used in adults...
  82. pmc The IL-17 differentiation pathway and its role in transplant outcome
    Jonathan S Serody
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Biol Blood Marrow Transplant 18:S56-61. 2012
    ..Here we discuss the IL-17 pathway of T cell differentiation and the accumulating evidence suggesting it represents an important new target for the control of deleterious alloimmune responses...
  83. pmc Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
    Meng Lv
    Peking University People s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No 11 Xizhimen South Street, Beijng 100044, China
    J Hematol Oncol 5:10. 2012
    ..This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China...
  84. ncbi A comparison of allografting with autografting for newly diagnosed myeloma
    Benedetto Bruno
    San Giovanni Battista Hospital, University of Turin, Turin, Italy
    N Engl J Med 356:1110-20. 2007
    ..In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts...
  85. pmc Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse
    Benny J Chen
    Division of Cellular Therapy Bone Marrow Transplantation, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 109:3115-23. 2007
    ..The abortive immune response, which was mediated by non-alloantigen-specific memory T cells in response to alloantigens, may explain why memory T cells from unprimed and non-alloantigen-primed donors could not induce GVHD...
  86. ncbi Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources
    Christopher M Walker
    Division of Infectious Diseases, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455 0250, USA
    Biol Blood Marrow Transplant 13:1106-15. 2007
    ..Recipients of UCB have similar risks of CMV infection, responses to antiviral therapy, and survival following CMV infection as recipients of either marrow or PBSC...
  87. pmc Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age
    Scott Samuelson
    University of Utah, Department of Medicine, Salt Lake City, UT, USA
    Br J Haematol 153:76-82. 2011
    ..Motivated older patients with myelofibrosis without substantial comorbid conditions should be offered the option of allogeneic HCT...
  88. ncbi Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays
    Tamotsu Ichiba
    Department of Internal Medicine, University of Michigan Cancer Center, Ann Arbor, USA
    Blood 102:763-71. 2003
    ....
  89. ncbi Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention
    Aline Gaidot
    Immunology Immunopathology Immunotherapy I3, Université Pierre et Marie Curie UPMC, université Paris 06, Unité Mixte de Recherche UMR 7211, Paris, France
    Blood 117:2975-83. 2011
    ..Taken together, these results suggest that rsTreg GVHD prevention is associated with improved early immune reconstitution in a model that more closely approximates the biology of allogeneic HSCT in human adults...
  90. ncbi The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation
    H Olkinuora
    Children s Hospital, Division of Hematology Oncology and Stem Cell Transplantation, Helsinki University Central Hospital, Helsinki, Finland
    Scand J Immunol 73:586-93. 2011
    ..Early viral infections linked with prolonged T cell immunodeficiency and thymic dysfunction may be indicative of the presence of subclinical GVHD...
  91. ncbi The role of B cells in the pathogenesis of graft-versus-host disease
    Alexander Shimabukuro-Vornhagen
    Laboratory for Tumor and Transplantation Immunology, Stem Cell Transplantation Program and Max Eder Junior Research Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Blood 114:4919-27. 2009
    ....
  92. pmc Epithelial mesenchymal transition in human ocular chronic graft-versus-host disease
    Yoko Ogawa
    Department of Ophthalmology, Keio University, School of Medicine, Shinjuku ku, Tokyo, Japan
    Am J Pathol 175:2372-81. 2009
    ..Our findings suggest that EMT may be partially responsible for the conjunctival and lacrimal gland fibrosis found in patients with cGVHD...
  93. pmc Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD
    Afonso C Vigorito
    Bone Marrow Transplant Program at the State University of Campinas, Sao Paulo, Brazil
    Blood 114:702-8. 2009
    ..Our results support the consensus recommendation that, with appropriate stratification, clinical trials can include patients with late acute GVHD as well as those with NIH chronic GVHD...
  94. pmc Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease
    K L Hippen
    Department of Pediatrics, Division of Hematology Oncology and Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, MN, USA
    Am J Transplant 11:1148-57. 2011
    ..Most importantly, Rapa/TGFß iTregs suppress disease in a xenogeneic model of GVHD. This study opens the door for iTreg cellular therapy for human diseases...
  95. ncbi Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin
    Maria Teresa Van Lint
    Divisione Ematologia 2, Ospedale San Martino, 16132 Genoa, Italy
    Blood 107:4177-81. 2006
    ....
  96. ncbi High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases
    Libuse Tauchmanova
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Cancer 95:1076-84. 2002
    ..The extent to which chemotherapy and immune system derangement affect endocrine function in allo-BMT recipients is still unclear...
  97. ncbi Induction of GVHD-like skin disease by passively transferred CD8(+) T-cell receptor transgenic T cells into keratin 14-ovalbumin transgenic mice
    Akihiko Shibaki
    Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Invest Dermatol 123:109-15. 2004
    ....
  98. pmc A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
    Davide Bagnara
    The Feinstein Institute for Medical Research, North Shore LIJ Health System, 350 Community Drive, Manhasset, NY 11030, USA
    Blood 117:5463-72. 2011
    ....
  99. ncbi Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients
    P R Fallen
    Anthony Nolan Research Institute, and Department of Haematology, Royal Free and University College Medical School, Royal Free Campus, Fleet Road, Hampstead, London NW3 2QG, UK
    Bone Marrow Transplant 32:1001-14. 2003
    ..This study suggests that future analysis of the factors affecting T cell reconstitution and studies aimed at reactivating the thymus through therapeutic intervention should be analysed in age-, GVHD- and TCD-matched patient groups...
  100. pmc Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects
    J Joseph Melenhorst
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 116:4700-2. 2010
    ..These data indicate that the adoptive transfer of partially HLA-mismatched virus-specific CTL is safe despite in vitro recognition of recipient HLA molecules...
  101. ncbi Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
    Jurgen Finke
    Department of Hematology and Oncology, Universitatsklinikum Freiburg, Germany
    Lancet Oncol 10:855-64. 2009
    ..We did a prospective, randomised, multicentre, open-label, phase 3 trial to compare standard GVHD prophylaxis with ciclosporin and methotrexate with or without anti-Jurkat ATG-Fresenius (ATG-F)...

Research Grants64

  1. Inhibition of IkK to treat lethal Graft-vs.-Host Disease
    Patrick Flood; Fiscal Year: 2009
    ..Experiments are proposed in animal models to test the activity of the compound and if successful the long-term goal of this work is to take this compound in human clinical trials for the treatment of GVHD. ..
  2. Neonatal Chemoselection Following Ex Vivo Gene Transfer For Hereditary Disorders
    KARIN L GAENSLER; Fiscal Year: 2012
    ..abstract_text> ..
  3. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2013
    ..We therefore anticipate rapid translation of the optimized promising pretargeted RIT into our clinical RIT HCT program for AML and MDS. ..
  4. Regulation of Chronic Colitis by Mesenchymal Stem Cells
    Matthew B Grisham; Fiscal Year: 2013
    ..abstract_text> ..
  5. IL-22 in epithelial regeneration after allogeneic transplant
    Alan Hanash; Fiscal Year: 2013
    ..In addition, the career development goal of this project is to help Dr. Hanash transition into an independent investigator with his own laboratory and R01 funding. ..
  6. ROCK inhibitor suppression of GVHD with retention of GVL response
    Sujatha Iyengar; Fiscal Year: 2012
    ..Using ROCK inhibitors for GVHD is novel, and success would accelerate our long term goal of using ROCK inhibitors with BMT, to treat leukemias and other tumors. ..
  7. Modeling oxidative stress and DNA damage using GI organotypic culture systems
    John P Lynch; Fiscal Year: 2013
    ..It will also foster the development of novel therapeutic and preventive strategies that will improve patient care for these important clinical conditions. ..
  8. Chronic kidney disease in survivors of hematopoietic cell transplant
    Sangeeta Hingorani; Fiscal Year: 2012
    ..abstract_text> ..
  9. Transplant Associated Infection Surveillance Network Phase II
    PETER GEORGE PAPPAS; Fiscal Year: 2012
    ..This consortium is very well positioned to accomplish the goals set forth in this announcement. ..
  10. Lentivirus-based positive/negative selection in minimally ablative transplants
    KARIN L GAENSLER; Fiscal Year: 2013
    ....
  11. Regulation of CD8+ T Cell Homeostatis by IL-4
    FRED DOUGLASS FINKELMAN; Fiscal Year: 2012
    ..abstract_text> ..
  12. HTS ASSAYS FOR INHIBITORS OF PROTEIN INTERACTIONS INCLUDING MLCK1-FKBP8
    Jerrold R Turner; Fiscal Year: 2012
    ..In addition, the TR-FRET approach will yield robust high throughout screens to identify agents that modulate a wide variety of PPIs in live cells. ..
  13. Therapeutic-Expression of a Platelet-Specific Integrin
    DAVID ALLEN WILCOX; Fiscal Year: 2010
    ..This study should lead to the development of safe and effective methods for human gene therapy for inherited platelet bleeding disorders and other diseases of hemostasis. ..
  14. Role of the thymic epithelium on the outcome of allogeneic transplantation
    Konstantina Alexandropoulos; Fiscal Year: 2013
    ....
  15. Role of Tissue Antigen Presenting Cells in GVHD
    Warren D Shlomchik; Fiscal Year: 2013
    ....
  16. GVL Resistance: Immune selection, T cell ignorance and T cell exhaustion
    Warren D Shlomchik; Fiscal Year: 2013
    ..These studies will identify GVL resistance mechanisms with this approach and similar resistance mechanisms are likely in play in alloimmune responses without donor vaccination. ..
  17. Characterization of Chronic Graft-Versus-Host Disease in the Canine Model
    SCOTT STOLL GRAVES; Fiscal Year: 2013
    ....
  18. Cord Blood Expansion Inside a Bioengineered Liver
    Shay Soker; Fiscal Year: 2013
    ..Upon completion, these studies will add to the understanding of how fetal liver niches support HSC expansion, and, more importantly, will allow the development of a novel strategy to functionally expand CB-HPSC. ..
  19. NK Cells in GVHD and GVT
    Robert S Negrin; Fiscal Year: 2012
    ..of natural killer cells which have the unique capabilities of improving anti-tumor effects without causing graft vs host disease. We hope to understand the mechanisms of improved graft vs...
  20. Blood and Marrow Transplant Clinical Trials Network
    Michael A Pulsipher; Fiscal Year: 2013
    ..The PBMTC Core Center proposal alms to improve survival using a novel approach to treat hemophagocytic disorders. ..
  21. The role of commensal bacteria in enhanced GVHD due to Atg16L1 mutation - Resubmi
    ALEXANDRIA K MAURER; Fiscal Year: 2013
    ..Additional, we hope to elucidate novel gene-commensal interactions that will lead to insight into intestinal bacteria and disease in general. ..
  22. Analysis of Morbidity and Mortality Among Hematopoietic Cell Transplantation Surv
    ERIC JESSEN CHOW; Fiscal Year: 2013
    ..Findings also will be directly relevant to the larger population of cancer patients who often receive similar treatment exposures. ..
  23. Transfusion of Donor Effector Memory T Cells for GVL and Immune Reconstitution
    Warren D Shlomchik; Fiscal Year: 2013
    ....
  24. IND 20212 (03-25-99) PHASE 2: ORBEC (ORAL BDP)-PATIENTS WITH CHRONIC GVHD
    CHRISTOPHER JOSEPH SCHABER; Fiscal Year: 2013
    ..Upon completion of the Phase 2 clinical study, Soligenix will be in a position to begin the process for a Phase 3 FDA reviewed and accepted clinical study, on the road to the first drug to be approved for treatment for cGVHD. ..
  25. Glucose Transport in Regulation of T Cell Activation and Inflammation
    Jeffrey C Rathmell; Fiscal Year: 2012
    ....
  26. MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS
    Rainer F Storb; Fiscal Year: 2013
    ..This is especially important since median ages at diagnosis of patients with most candidate diseases range from 65 to 70 years, which is beyond the age range of inclusion in conventional myeloablative HCT regimens. ..
  27. Improving the Outcomes of Stem Cell Transplantation
    Richard E Champlin; Fiscal Year: 2013
    ..We are committed to the success of the BMT-CTN and continue to be leaders in the organization. We are a major contributor to the development of BMT-CTN studies and active accrue patients to its studies. ..
  28. Cytokine Induced CD26 Modulation of Adult Hematopoietic Stem Cell Trafficking
    Kent Christopherson; Fiscal Year: 2009
    ..Furthermore, we anticipate that with the appropriate subsequent research and clinical trials this research will have a positive impact on the survival of cord blood stem cell transplant patients. ..
  29. Analysis of human NKT cells in GVHD in vivo
    Jenny E Gumperz; Fiscal Year: 2013
    ....
  30. Enhancing the Safety of Allogeneic Transplantation
    Daniel J Weisdorf; Fiscal Year: 2013
    ..Improving engraftment and post transplant immune recovery may limit these hazards and augment the success of all transplantation. ..
  31. BONE MARROW GRAFTING FOR LEUKEMIA AND LYMPHOMA
    Robert S Negrin; Fiscal Year: 2013
    ..The PPG is composed of five interactive Projects and four Cores focused on the themes of graft vs host disease biology and prevention, disease relapse treatment and prevention and immune reconstitution...
  32. Regulatory T Cells in Allogeneic Transplantation
    Robert S Negrin; Fiscal Year: 2010
    ..Preliminary studies, so far, have demonstrated favorable results with this specific type of transplant. ..
  33. Enhancing Engraftment of Cord Blood by CD26 Inhibition
    Sherif S Farag; Fiscal Year: 2013
    ....
  34. Blood &Marrow Clinical Trials Network - Hutchinson Center Core Clinical Sit
    Frederick Appelbaum; Fiscal Year: 2013
    ..The Blood &Marrow Clinical Trial Network uses a multicenter approach to effectively conduct clinical trials of novel therapies in patients with uncommon conditions. ..
  35. Investigation of the Molecular Basis of T Cell Alloreactivity
    GERALD PATRICK MORRIS; Fiscal Year: 2013
    ..Molecular Definition of the Alloreactive T Cell Receptor Repertoire ..
  36. Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Transplantation
    Daniel J Weisdorf; Fiscal Year: 2010
    ..End of abstract.) ..
  37. DC-HIL in Cutaneous Immunity
    Kiyoshi Ariizumi; Fiscal Year: 2013
    ..regulatory Tcells in vivo. Our new findings should lead to application of the DC- HIL/SD-4 pathway for biologic and/or pharmacologic benefit. ..
  38. Nebraska Blood and Marrow Transplant Research Network
    JULIE MARIE VOSE; Fiscal Year: 2010
    ..End of abstract.) ..
  39. Blood and Marrow Clinical Research Network
    Frederick Appelbaum; Fiscal Year: 2010
    ..The Center is deeply committed to cooperative clinical research and can provide an outstanding environment in which to conduct the sorts of studies described with state-of-the-art clinical and laboratory facilities. (End of abstract.) ..
  40. BMT Clinical Research Network Data Coordinating Center
    MARY MARESCA HOROWITZ; Fiscal Year: 2010
    ..The DCC will continue comprehensive administrative, contracting, statistical and scientific activities to facilitate efficient use of Network resources and design and execution of high quality clinical trials. (End of abstract.) ..
  41. BMT Clincal Trial Network at Stanford
    Ginna G Laport; Fiscal Year: 2010
    ..End of abstract.) ..
  42. Core Clinical Center for BMT Clinical Research Network
    John R Wingard; Fiscal Year: 2010
    ..End of abstract.) ..
  43. Blood and Marrow Transplant Clinical Research Network
    Stephen J Forman; Fiscal Year: 2010
    ..End of abstract.) ..
  44. IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS
    Sergio A Giralt; Fiscal Year: 2010
    ..End of abstract.) ..
  45. NHLBI Blood /Marrow Transplant Clinical Research Network
    Hillard M Lazarus; Fiscal Year: 2010
    ..abstract_text> ..
  46. Effect of recipient age /graft vs host disease post BMT
    RAYMOND HUTCHISON; Fiscal Year: 2001
    ..abstract_text> ..
  47. HEPATIC LESIONS IN MURINE CHRONIC GRAFT-VS-HOST DISEASE
    John Vierling; Fiscal Year: 1991
    ..Clones will be established both by selection of T cells proliferating in response to IL-2 in vitro and by selection of antigen- specific T cells proliferating in response to simulation with isolated bile duct epithelial cells...
  48. Novel Immunotoxins for Depletion of Dendritic Cells
    Warren Shlomchik; Fiscal Year: 2005
    ..The goal of our work is to prevent this attack, thereby making this therapy safer and more widely applicable ..
  49. Genetic Variation in Vitamin D Metabolism and BMT Outcomes
    KIMBERLY ROBIEN; Fiscal Year: 2009
    ....
  50. Genetic Manipulation of T Cells--PreClinical Models
    John Dipersio; Fiscal Year: 2005
    ..Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. ..
  51. FACILITATING CELL INDUCED TOLERANCE IN ORGAN TRANSPLANTS
    Yolonda Colson; Fiscal Year: 2001
    ..In Aim III, we will Determine the Mechanism by Which The FC Facilitates SC Survival: Are CD3AMs Necessary for SC Rescue? ..
  52. EFFECT OF PRIOR DONOR PREGNANCY ON GRAFT-VS-HOST DISEASE
    JAMES OKUNEWICK; Fiscal Year: 1993
    ..Finally, the possibility of using selective T-depletion techniques to manipulate the donor cells and reduce the intensity of the allosensitization will also be examined...
  53. IMMUNOGENOMICS OF GRAFT VS HOST DISEASE
    Derry Roopenian; Fiscal Year: 2003
    ..The applicant's proposed studies should resolve this enigma, and in doing so, the studies should clarify the immunogenetics of GVHD and provide a feasibility study of how genomic data might be exploited to improve allogeneic BMT. ..
  54. CD4 Regulator T Cells Suppress Alloreactivity after BMT
    Bryon Johnson; Fiscal Year: 2005
    ..The information obtained will contribute significantly to our understanding of the role of regulatory T cells in mediating dominant peripheral tolerance after allo-BMT and could lead to translational applications in clinical BMT. ..
  55. Mechanism of Facilitating Cell-Mediated Tx Tolerance
    Yolonda Colson; Fiscal Year: 2007
    ..In AIM Ill, we will Determine the Mechanism of FC-Mediated Transplantation Tolerance. ..
  56. ALLO STEM CELL TRANSPLANT. FOR HIGH RISK HEMOTOLOGIC CA
    Gordon Phillips; Fiscal Year: 2000
    ..In addition, the degree of oxidant stress, activation of the NF-kappabeta, and circulating levels of inflammatory factors will be compared (admittedly in a non-definitive fashion) with the outcome measures. ..
  57. SYNGENEIC GRAFT-VS-HOST DISEASE
    Allan Hess; Fiscal Year: 2000
    ..These studies will define some of the immunobiological mechanisms involved in this unique autoaggression syndrome. ..